Increased BRAF copy number in lung adenocarcinoma

Sasaki,Hidefumi; Maekawa,Masahiko; Tatematsu,Tsutomu; Okuda,Katsuhiro; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/ol.2014.2719

Increased BRAF copy number in lung adenocarcinoma

Authors:
- Hidefumi Sasaki
- Masahiko Maekawa
- Tsutomu Tatematsu
- Katsuhiro Okuda
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467‑8601, Japan, GSP Lab Inc., Kawasaki, Kanagawa 212‑0032, Japan
Published online on: November 20, 2014 https://doi.org/10.3892/ol.2014.2719
Pages: 709-712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Point mutation of the BRAF gene is a genetic event that occurs in a subset of lung adenocarcinoma cases. For example, BRAF V600E is a driver mutation that can be effectively targeted using selective BRAF and/or MEK inhibitors. The present study hypothesized that an increase in BRAF copy number may be correlated with certain clinicopathological features of lung adenocarcinoma in Japanese patients. The BRAF gene copy number was analyzed using quantitative polymerase chain reaction amplifications in 29 surgically treated lung adenocarcinoma cases without EGFR or Kras mutations from Nagoya City University Hospital (Nagoya, Japan). Seven BRAF‑mutant cases were included. Increased BRAF gene copy number was identified in three lung adenocarcinoma patients (10.3%), all of which exhibited the V600E mutation. Using fluorescence in situ hybridization with BRAF‑specific and chromosome 7 centromeric probes, increased copy number status was associated with gene amplification or gain of chromosome 7. Although increased BRAF copy number was correlated with BRAF V600E mutations, numerical changes in BRAF copy number were rare and mild in lung adenocarcinoma, resulting in no significant difference in pathological tumor status or tumor stage.

View Figures

View References

1	Ginsberg RJ, Kris MK and Armstrong JG: Cancer of the lung. Principles and Practice of Oncology. 4th edition. JB Lippincott; Philadelphia, PA: pp. 673–682. 1993
2	Amano J, Kuwano H and Yokomise H: Thoracic and cardiovascular surgery in Japan during 2011: Annual report by the Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 61:578–607. 2013. View Article : Google Scholar : PubMed/NCBI
3	Postus PE: Chemotherapy for non-small cell lung cancer: the experience of the Lung Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Chest. 113(Suppl 1): 28S–31S. 1997. View Article : Google Scholar
4	Ding L, Getz G, Wheeler DA, et al: Somatic mutations affect key pathways in lung adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sun Y, Ren Y, Fang Z, et al: Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol. 28:4616–4620. 2010. View Article : Google Scholar : PubMed/NCBI
6	Weir BA, Woo MS, Getz G, et al: Characterizing the cancer genome in lung adenocarcinoma. Nature. 450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
7	Gautschi O, Pauli C, Srobel K, et al: A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib. J Thorac Oncol. 7:e23–e24. 2012. View Article : Google Scholar : PubMed/NCBI
8	Falchook GS, Long GV, Kurzrock R, et al: Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumors: a phase 1 dose-escalation trial. Lancet. 379:1893–1901. 2012. View Article : Google Scholar : PubMed/NCBI
9	Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI
10	Flaherly KT, Infante JR, Daud A, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600E mutations. N Engl J Med. 367:1694–1703. 2012. View Article : Google Scholar
11	Flaherly KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 367:107–114. 2012. View Article : Google Scholar
12	Marchetti A, Felicioni L, Malatesta S, et al: Clinical features and outcome of patients with non-small-cell lung cancer haboring BRAF mutations. J Clin Oncol. 29:3574–3579. 2011. View Article : Google Scholar : PubMed/NCBI
13	Cardarella S, Ogino A, Nishio M, et al: Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
14	Sasaki H, Shitara M, Yokota K, et al: Braf and erbB2 mutations correlate with smoking status in lung cancer patients. Exp Ther Med. 3:771–775. 2012.PubMed/NCBI
15	Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas haboring BRAF mutations. J Clin Oncol. 29:2046–2051. 2011. View Article : Google Scholar : PubMed/NCBI
16	Sasaki H, Shimizu S, Tani Y, et al: Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma. Lung Cancer. 82:51–54. 2013. View Article : Google Scholar : PubMed/NCBI
17	Pratilas CA, Hanrahan AJ, Halilovic E, et al: Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res. 68:9375–9383. 2008. View Article : Google Scholar : PubMed/NCBI
18	Wan PT, Garnett MJ, Roe SM, et al; Cancer Genome Project. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
19	Ciampi R, Zhu Z and Nikiforov YE: BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol. 16:99–105. 2005. View Article : Google Scholar : PubMed/NCBI
20	Endo K, Sasaki H, Yano M, et al: Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy. Oncol Rep. 16:533–541. 2006.PubMed/NCBI
21	Sasaki H, Okuda K, Kawano O, et al: Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. Oncol Rep. 18:623–628. 2007.PubMed/NCBI
22	Wang TL, Maierhofer C, Speicher MR, et al: Digital karyotyping. Proc Natl Acad Sci USA. 99:16156–16161. 2002. View Article : Google Scholar : PubMed/NCBI
23	Cardarella S, Ogino A, Nishino M, et al: Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res. 19:4532–4540. 2013. View Article : Google Scholar : PubMed/NCBI
24	Marchetti A, Felicioni L, Malatesta S, et al: Clinical features and outcome of patients with non-small-cell lung cancer haboring BRAF mutations. J Clin Oncol. 29:3574–3579. 2011. View Article : Google Scholar : PubMed/NCBI
25	De Oliveira Duarte Achcar R, Nikiforova MN and Yousem SA: Micropappillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. Am J Clin Pathol. 131:694–700. 2009. View Article : Google Scholar : PubMed/NCBI
26	Rudin CM, Hong K and Streit M: Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in patient with BRAF-mutant non-small-cell lung cancer. J Thorac Oncol. 8:e41–e42. 2013.PubMed/NCBI
27	El-Naggar AK, Dinh M, Tucker SL, et al: Numerical chromosomal changes in DNA hypodiploid solid tumors; restricted loss and gain of certain chromosomes. Cytometry. 37:107–112. 1999. View Article : Google Scholar : PubMed/NCBI
28	Balsara BR, Sonoda G, du Manoir S, et al: Comparative genomic hybridization analysis detects frequent, often high-level, overrepresentation of DNA sequences at 3q, 5p, 7p, and 8q in human non-small cell lung carcinomas. Cancer Res. 57:2116–2120. 1997.PubMed/NCBI
29	Ubagai T, Matsuura S, Tauchi H, et al: Coparative genomic hybridization analysis suggests a gain of chromosome 7p associated with lymph node metastasis in non-small cell lung cancer. Oncol Rep. 8:83–88. 2001.
30	Garnis C, Lockwood WW, Vucic E, et al: High resolution analysis of non-small cell lung cancer cell lines by whole genome tiling path array CGH. Int J Cancer. 118:1556–1564. 2006. View Article : Google Scholar